Darlene Floden1, Scott E Cooper2, Sandra D Griffith2, Andre G Machado2. 1. From the Center for Neurological Restoration (D.F., S.E.C., A.G.M.) and Department of Quantitative Health Sciences (S.D.G.), Cleveland Clinic, OH. flodend@ccf.org. 2. From the Center for Neurological Restoration (D.F., S.E.C., A.G.M.) and Department of Quantitative Health Sciences (S.D.G.), Cleveland Clinic, OH.
Abstract
OBJECTIVES: To examine disease, treatment, cognitive, and psychological factors associated with quality of life (QoL) before and after surgery and assess the ability to predict QoL outcomes. METHODS: We identified a retrospective, cross-sectional sample of 85 patients with Parkinson disease who underwent subthalamic deep brain stimulation (DBS). Patients' QoL was categorized as "improved" and "stable/worsened" using reliable change indices. Univariate correlational analyses identified relationships between Parkinson's Disease Questionnaire-39 ratings and disease (Unified Parkinson's Disease Rating Scale-III [UPDRS-III] motor scores on and off medications, disease duration), treatment (medication burden, unilateral vs bilateral DBS), cognitive (neuropsychological battery), and psychological (depression) variables. Step-wise multiple linear regression and logistic regression models included selected preoperative variables to predict change in QoL ratings and QoL outcome after surgery. RESULTS: Fifty-one percent of patients reported clinically significant improvements in QoL while 47% reported stable QoL and 2% worsened. Motor scores (UPDRS-III) were not relevant to QoL changes, potentially because of the rarity of poor motor outcomes, while single-trial learning and depression scores were the most important variables in predicting QoL changes. There was a subtle additional benefit to undergoing bilateral subthalamic nucleus DBS. CONCLUSIONS: The findings provide greater insight into the nonmotor features that contribute to the success of subthalamic nucleus DBS procedures from the patient's perspective and raise questions about the treatment focus and emphasis on symptom profiles in DBS candidacy evaluations.
OBJECTIVES: To examine disease, treatment, cognitive, and psychological factors associated with quality of life (QoL) before and after surgery and assess the ability to predict QoL outcomes. METHODS: We identified a retrospective, cross-sectional sample of 85 patients with Parkinson disease who underwent subthalamic deep brain stimulation (DBS). Patients' QoL was categorized as "improved" and "stable/worsened" using reliable change indices. Univariate correlational analyses identified relationships between Parkinson's Disease Questionnaire-39 ratings and disease (Unified Parkinson's Disease Rating Scale-III [UPDRS-III] motor scores on and off medications, disease duration), treatment (medication burden, unilateral vs bilateral DBS), cognitive (neuropsychological battery), and psychological (depression) variables. Step-wise multiple linear regression and logistic regression models included selected preoperative variables to predict change in QoL ratings and QoL outcome after surgery. RESULTS: Fifty-one percent of patients reported clinically significant improvements in QoL while 47% reported stable QoL and 2% worsened. Motor scores (UPDRS-III) were not relevant to QoL changes, potentially because of the rarity of poor motor outcomes, while single-trial learning and depression scores were the most important variables in predicting QoL changes. There was a subtle additional benefit to undergoing bilateral subthalamic nucleus DBS. CONCLUSIONS: The findings provide greater insight into the nonmotor features that contribute to the success of subthalamic nucleus DBS procedures from the patient's perspective and raise questions about the treatment focus and emphasis on symptom profiles in DBS candidacy evaluations.
Authors: Simon Hanslmayr; Gregor Volberg; Maria Wimber; Markus Raabe; Mark W Greenlee; Karl-Heinz T Bäuml Journal: J Neurosci Date: 2011-11-02 Impact factor: 6.167
Authors: Günther Deuschl; Carmen Schade-Brittinger; Paul Krack; Jens Volkmann; Helmut Schäfer; Kai Bötzel; Christine Daniels; Angela Deutschländer; Ulrich Dillmann; Wilhelm Eisner; Doreen Gruber; Wolfgang Hamel; Jan Herzog; Rüdiger Hilker; Stephan Klebe; Manja Kloss; Jan Koy; Martin Krause; Andreas Kupsch; Delia Lorenz; Stefan Lorenzl; H Maximilian Mehdorn; Jean Richard Moringlane; Wolfgang Oertel; Marcus O Pinsker; Heinz Reichmann; Alexander Reuss; Gerd-Helge Schneider; Alfons Schnitzler; Ulrich Steude; Volker Sturm; Lars Timmermann; Volker Tronnier; Thomas Trottenberg; Lars Wojtecki; Elisabeth Wolf; Werner Poewe; Jürgen Voges Journal: N Engl J Med Date: 2006-08-31 Impact factor: 91.245
Authors: M C Rodriguez-Oroz; J A Obeso; A E Lang; J-L Houeto; P Pollak; S Rehncrona; J Kulisevsky; A Albanese; J Volkmann; M I Hariz; N P Quinn; J D Speelman; J Guridi; I Zamarbide; A Gironell; J Molet; B Pascual-Sedano; B Pidoux; A M Bonnet; Y Agid; J Xie; A-L Benabid; A M Lozano; J Saint-Cyr; L Romito; M F Contarino; M Scerrati; V Fraix; N Van Blercom Journal: Brain Date: 2005-06-23 Impact factor: 13.501
Authors: Frances M Weaver; Kenneth Follett; Matthew Stern; Kwan Hur; Crystal Harris; William J Marks; Johannes Rothlind; Oren Sagher; Domenic Reda; Claudia S Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff Bronstein; Gatana Stoner; Jill Heemskerk; Grant D Huang Journal: JAMA Date: 2009-01-07 Impact factor: 56.272
Authors: Laura B Zahodne; Michael S Okun; Kelly D Foote; Hubert H Fernandez; Ramon L Rodriguez; Samuel S Wu; Lindsey Kirsch-Darrow; Charles E Jacobson; Christian Rosado; Dawn Bowers Journal: J Neurol Date: 2009-04-12 Impact factor: 4.849
Authors: Harriet M M Smeding; Johannes D Speelman; Hilde M Huizenga; P Richard Schuurman; Ben Schmand Journal: J Neurol Neurosurg Psychiatry Date: 2009-05-21 Impact factor: 10.154
Authors: Sophie Langner-Lemercier; Sophie Drapier; Florian Naudet; Nathalie Le Clanche; Jean-François Houvenaghel; Paul Sauleau; Pierre Jannin; Claire Haegelen; Florence Le Jeune; Marc Vérin Journal: J Neurol Date: 2015-01-30 Impact factor: 4.849
Authors: Tomas Cartmill; David Skvarc; Richard Bittar; Jane McGillivray; Michael Berk; Linda K Byrne Journal: Neuropsychol Rev Date: 2021-02-19 Impact factor: 7.444
Authors: Vitalii V Cozac; Michael M Ehrensperger; Ute Gschwandtner; Florian Hatz; Antonia Meyer; Andreas U Monsch; Michael Schuepbach; Ethan Taub; Peter Fuhr Journal: Front Aging Neurosci Date: 2016-06-08 Impact factor: 5.750